After priming with the SARS-S protein exosomal vaccine and boosting with the adenoviral vector the neutralizing antibody titers of using SARS-S protein exosomal vaccine exceeded those observed in the convalescent serum of SARS patients (Kuate, et al., 2007). This evidence concerns the gene PROS1 and severe acute respiratory syndrome.